Autolus Therapeutics (NASDAQ:AUTL) Stock Rating Upgraded by Wall Street Zen

Autolus Therapeutics (NASDAQ:AUTL) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Sunday.

Several other equities research analysts have also weighed in on AUTL. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Weiss Ratings lowered Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 31st. Finally, Jefferies Financial Group raised Autolus Therapeutics to a “strong-buy” rating in a report on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.00.

Autolus Therapeutics Stock Up 6.0%

AUTL stock opened at $2.28 on Friday. The firm has a market cap of $606.84 million, a PE ratio of -2.15 and a beta of 2.07. Autolus Therapeutics has a 12 month low of $1.17 and a 12 month high of $2.43. The company has a debt-to-equity ratio of 1.04, a current ratio of 4.89 and a quick ratio of 4.40. The firm has a 50 day simple moving average of $1.66 and a 200 day simple moving average of $1.58.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.06. The firm had revenue of $45.69 million for the quarter, compared to analyst estimates of $38.56 million. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. Equities research analysts forecast that Autolus Therapeutics will post -0.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Several hedge funds have recently bought and sold shares of the business. Mak Capital One LLC grew its stake in Autolus Therapeutics by 15.3% during the 4th quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock valued at $59,711,000 after acquiring an additional 3,987,727 shares in the last quarter. Armistice Capital LLC lifted its position in shares of Autolus Therapeutics by 12.2% in the fourth quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock worth $34,825,000 after purchasing an additional 1,900,000 shares in the last quarter. Syncona Portfolio Ltd purchased a new stake in shares of Autolus Therapeutics in the second quarter worth approximately $26,625,152,000. Schroder Investment Management Group boosted its holdings in shares of Autolus Therapeutics by 12.5% during the fourth quarter. Schroder Investment Management Group now owns 9,489,345 shares of the company’s stock worth $18,694,000 after purchasing an additional 1,056,092 shares during the period. Finally, Bank of America Corp DE boosted its holdings in shares of Autolus Therapeutics by 108.1% during the third quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock worth $3,308,000 after purchasing an additional 1,054,458 shares during the period. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.